Study to efficacy of Ivermectin in patients of COVID-19
Phase 2
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/05/025224
- Lead Sponsor
- R D Gardi Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Adults (age >=18 years to <=75 years) 2. Laboratory-confirmed SARS-CoV-2 infection and, in the view of the responsible doctor, no contra-indication to any of the study treatments 3. Hospitalized at R D Gardi Medical College, Ujjain Madhya Pradesh
Exclusion Criteria
1. Anticipated transfer to another hospital, within 72 hours, which is not a study site 2. Known allergy to study medication or its components (non-medicinal ingredients) 3. Known HIV infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect of Ivermectin on eradication of virus. <br/ ><br>Test for virus at 1, 3 and 5 days from beginning of trial drug started for the patient in the hospital <br/ ><br>Timepoint: 3 months
- Secondary Outcome Measures
Name Time Method 1. Overall safety of the study drug <br/ ><br>2. Duration of hospitalization <br/ ><br>3. Improvement in the abnormal laboratory valuesTimepoint: 3 months